Quality by design for biopharmaceuticals

By A. Rathore, H. Winkle. Nature Biotechnology, 2009

846 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/ebf257e162ead722416ba391f02bb34edaf005ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Robert Langer
2. V. Préat
3. F. Danhier

In Molecular Biology

1. F. Danhier
2. Robert Langer
3. Daniel G. Anderson
4. V. Préat
5. Héloïse Ragelle
6. Jun Wu
7. O. Farokhzad

Citations in the corpus

• Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017, background): “This necessitates cooperation between R&D, QC, and manufacturing subdivisions [46].”
• When Risks Cannot Be Seen: Regulating Uncertainty in Emerging Technologies (2017, neutral): “Rathore and Winkle (2009) suggest that the uncertainty surrounding regulatory aspects of new pharmaceutical technologies causes reluctance among manufacturers to adopt innovations.”